Fresenius Kabi now has four FDA-approved biosimilars. Image credit: Shutterstock/ JHVEPhoto. Fresenius Kabi and Formycon have ...

As part of the deal, which could be worth $3.5bn, BMS will gain developmental support and therapeutic reagents from Prime ...

BioCryst Pharmaceuticals has received a contract valued at up to $69m from the US Department of Health and Human Services ...

Aktis Oncology, a clinical-stage biotechnology company, has announced the successful closure of a $175m Series B financing ...

BPGbio has received a Rare Pediatric Disease Designation from the US Food and Drug Administration (FDA) for BPM31510IV to ...

PD-1 inhibitors have revolutionised cancer treatment over the last decade, with their success attributed to Keytruda and ...

The European Commission approved Johnson and Johnson’s Yuvanci as the first single-pill combination therapy for PAH.

The manufacturing space at the Lexington facility will increase by an additional 24,000ft². Credit: Piramal Pharma ...

The retrospective study presented at ESMO 2024 involved about 2,400 patients with stage 3 or 4 non-small cell lung cancer.

GlobalData’s report assesses the drugs in the Bromodomain Testis Specific Protein pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development ...

GlobalData’s report assesses the drugs in the Aryl Hydrocarbon Receptor pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline.

GlobalData’s report assesses the drugs in the Cathepsin L1 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline.